Identifying genetic risks for complications in childhood cancer patients in Switzerland
Official title: Genetic Risks for Childhood Cancer Complications in Switzerland
Run by University Hospital, Geneva · NCT04702321 · Data updated 2026-11-12
This study is trying to find out if certain genetic differences can help explain the complications that childhood cancer patients in Switzerland might face after their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 21 Years |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 1 site (Geneva) |
| Status | Recruiting |
| Started | December 1, 2020 |
| Main results expected | December 31, 2037 |
| Study ends | December 31, 2037 |
| Registry record updated | January 13, 2021 |
| Trial ID | NCT04702321 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are childhood cancer patients registered in the Swiss Childhood Cancer Registry who have consented to participate in the biobank.
✕Probably not a fit
Patients who do not have a genetic predisposition to complications or those who have not consented to the biobank will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The GECCOS project aims to identify genetic variants linked to complications arising from childhood cancer treatments by analyzing germline genetic samples and clinical data from Swiss childhood cancer patients. This observational study utilizes data from the Germline DNA Biobank for Childhood Cancer and Blood Disorders in Switzerland, focusing on understanding how genetic differences can influence the severity and type of complications experienced by these patients. By correlating genetic information with clinical outcomes, the project seeks to enhance personalized care for childhood cancer survivors. This nationwide analysis has not been previously conducted in Switzerland.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment strategies for childhood cancer patients, minimizing complications and enhancing their quality of life.
How similar studies have gone: While this approach is novel in Switzerland, similar studies in other countries have shown success in linking genetic variants to treatment complications in childhood cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Registered in the Swiss Childhood Cancer Registry (SCCR) since 1976; AND 2. consented to the BaHOP (host biobank for the BISKIDS Biobanking project); AND 3. diagnosed with cancer according to the International Classification of Childhood Cancer, version 3, ICCC-3, or Langerhans cell histiocytosis (LCH) before age 21 years. Exclusion Criteria: 1. Lacking written consent signed by participant and/ or their legal representative to participate in the BaHOP (where applicable); OR 2. died after study participation and declined use of their samples and data after their death in the original consent for BaHOP (as indicated on the BaHOP consent).
Where it's running
-
University Hospital of Geneva
Geneva, Switzerland Recruiting
Study contacts
- Study coordinator: Marc Ansari, Prof
- Email: Marc.Ansari@hcuge.ch
- Phone: +41 79 553 61 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term health effects in childhood cancer survivors
This study looks at the long-term health effects that childhood cancer survivors in Switzerland may face as they grow up to help improve their care and quality of life.
-
Community-led, family-centered communication for Hispanic childhood cancer survivors
This study tests a family-focused communication approach to help young Hispanic adult survivors, their families, and clinicians talk more effectively about survivorship care.
-
Transition outcomes for adolescents and young adults with a cancer predisposition.
See if young adults with a genetic cancer predisposition establish and keep up care with adult providers and follow recommended cancer surveillance after they leave pediatric care at St. Jude.
-
Blood biomarkers for treatment-related brain injury in children with brain tumors
This project will test whether blood plasma biomarkers can show treatment-related brain injury in children with primary brain tumors by comparing those who receive radiotherapy, those who do not, and healthy children of the same age and sex.
-
How genes and alcohol interact to affect liver cancer risk
This project will test if certain gene variants together with alcohol use and metabolic problems raise the risk of liver cancer in people with fatty or cryptogenic liver disease, especially men with diabetes or obesity.
-
Topical 5% minoxidil to boost blood flow and skin‑flap survival during breast reconstruction
This trial will test whether applying 5% topical minoxidil to one breast before bilateral risk‑reducing mastectomy with immediate reconstruction improves blood flow and skin‑flap survival compared with a placebo on the other breast.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.